Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Autor: Dam T; Biogen, Cambridge, MA, USA. tien.dam@biogen.com., Boxer AL; Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA., Golbe LI; Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA., Höglinger GU; Department of Neurology, Technische Universität München, Munich, Germany.; German Center for Neurodegenerative Diseases, Munich, Germany.; Department of Neurology, Hanover Medical School, Hanover, Germany., Morris HR; National Hospital for Neurology and Neurosurgery, London, UK., Litvan I; University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA., Lang AE; Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada., Corvol JC; Sorbonne Université, Assistance Publique Hôpitaux de Paris, INSERM, CNRS, Institut du Cerveau - Paris Brain Institute - ICM, Hôpital Pitié-Salpêtrière, Paris, France., Aiba I; Department of Neurology, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan., Grundman M; University of California, Parkinson and Other Movement Disorders Center, San Diego, CA, USA.; Global R&D Partners, LLC, San Diego, CA, USA., Yang L; Biogen, Cambridge, MA, USA., Tidemann-Miller B; Biogen, Cambridge, MA, USA., Kupferman J; Biogen, Cambridge, MA, USA., Harper K; Biogen, Cambridge, MA, USA., Kamisoglu K; Biogen, Cambridge, MA, USA., Wald MJ; Biogen, Cambridge, MA, USA., Graham DL; Biogen, Cambridge, MA, USA., Gedney L; Biogen, Cambridge, MA, USA., O'Gorman J; Biogen, Cambridge, MA, USA., Haeberlein SB; Biogen, Cambridge, MA, USA.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2955-2956.
DOI: 10.1038/s41591-022-02076-8
Databáze: MEDLINE